Zeria's functional dyspepsia drug nears first filing
This article was originally published in Scrip
Executive Summary
Zeria and development partner Astellas are preparing to make an approval submission in Japan for acotiamide (Z-338), a potential first-in-class drug for functional dyspepsia (FD).